These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9846889)

  • 1. Factors in human serum interfere with the measurement of advanced glycation endproducts.
    Dorrian CA; Cathcart S; Clausen J; Shapiro D; Dominiczak MH
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1069-79. PubMed ID: 9846889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products.
    Mera K; Nagai M; Brock JW; Fujiwara Y; Murata T; Maruyama T; Baynes JW; Otagiri M; Nagai R
    J Immunol Methods; 2008 May; 334(1-2):82-90. PubMed ID: 18353354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycoxidation end products in commonly consumed foods.
    Goldberg T; Cai W; Peppa M; Dardaine V; Baliga BS; Uribarri J; Vlassara H
    J Am Diet Assoc; 2004 Aug; 104(8):1287-91. PubMed ID: 15281050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".
    Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B
    Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel application of surface plasmon resonance biosensor chips for measurement of advanced glycation end products in serum of Zucker diabetic fatty rats.
    Kim YS; Yi SY; Kim J; Kim M; Kim CS; Chung BH; Kim JS
    Biosens Bioelectron; 2009 Sep; 25(1):248-52. PubMed ID: 19589671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycated human serum albumin as AGE-carrier protein in enzyme-linked immunosorbent assay.
    Benko B; Turk Z
    Clin Lab; 2008; 54(9-10):331-9. PubMed ID: 19097490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of glycated nucleobases in human urine by a new monoclonal antibody specific for N2-carboxyethyl-2'-deoxyguanosine.
    Schneider M; Thoss G; Hübner-Parajsz C; Kientsch-Engel R; Stahl P; Pischetsrieder M
    Chem Res Toxicol; 2004 Oct; 17(10):1385-90. PubMed ID: 15487900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients.
    Zhang X; Frischmann M; Kientsch-Engel R; Steinmann K; Stopper H; Niwa T; Pischetsrieder M
    Clin Chem Lab Med; 2005; 43(5):503-11. PubMed ID: 15899672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
    Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
    Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
    Sebeková K; Podracká L; Heidland A; Schinzel R
    Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine.
    van Heijst JW; Niessen HW; Hoekman K; Schalkwijk CG
    Ann N Y Acad Sci; 2005 Jun; 1043():725-33. PubMed ID: 16037299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA).
    Newkirk MM; LePage K; Niwa T; Rubin L
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1129-38. PubMed ID: 9846895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of CML-modified proteins in hemofiltrate of diabetic patients by proteome analysis.
    Schmitt S; Linder M; Ständker L; Hammes HP; Preissner KT
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):26-34. PubMed ID: 17926233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan.
    Takeuchi M; Takino J; Furuno S; Shirai H; Kawakami M; Muramatsu M; Kobayashi Y; Yamagishi S
    PLoS One; 2015; 10(3):e0118652. PubMed ID: 25730321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody.
    Nagai R; Fujiwara Y; Mera K; Yamagata K; Sakashita N; Takeya M
    J Immunol Methods; 2008 Mar; 332(1-2):112-20. PubMed ID: 18242632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease.
    Kitamura M; Kitaichi N; Takeuchi M; Kitamei H; Namba K; Yamagishi SI; Iwabuchi K; Onoé K; Ohno S
    Br J Ophthalmol; 2005 Nov; 89(11):1407-9. PubMed ID: 16234440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional antibody against Nepsilon-(carboxymethyl)lysine (CML) shows cross-reaction to Nepsilon-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody.
    Koito W; Araki T; Horiuchi S; Nagai R
    J Biochem; 2004 Dec; 136(6):831-7. PubMed ID: 15671494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.